Coronavirus Disease 2019-Associated Invasive Fungal Infection.

Baddley, John W

Thompson, George R

Chen, Sharon C-A

White, P Lewis

Johnson, Melissa D

Nguyen, M Hong

Schwartz, Ilan S

Spec, Andrej

Ostrosky-Zeichner, Luis

Jackson, Brendan R

Patterson, Thomas F

Pappas, Peter G

2022-08-25T15:41:36Z

2022-08-25T15:41:36Z

2021-12

2022-08-25T15:41:35Z

Coronavirus disease 2019 (COVID-19) can become complicated by secondary invasive fungal infections (IFIs), stemming primarily from severe lung damage and immunologic deficits associated with the virus or immunomodulatory therapy. Other risk factors include poorly controlled diabetes, structural lung disease and/or other comorbidities, and fungal colonization. Opportunistic IFI following severe respiratory viral illness has been increasingly recognized, most notably with severe influenza. There have been many reports of fungal infections associated with COVID-19, initially predominated by pulmonary aspergillosis, but with recent emergence of mucormycosis, candidiasis, and endemic mycoses. These infections can be challenging to diagnose and are associated with poor outcomes. The reported incidence of IFI has varied, often related to heterogeneity in patient populations, surveillance protocols, and definitions used for classification of fungal infections. Herein, we review IFI complicating COVID-19 and address knowledge gaps related to epidemiology, diagnosis, and management of COVID-19-associated fungal infections.

ofab510

2328-8957

2328-8957

https://hdl.handle.net/10161/25603

eng

Oxford University Press (OUP)

Open forum infectious diseases

10.1093/ofid/ofab510

Aspergillus

COVID-19

Pneumocystis

SARS-CoV-2

candidiasis

endemic fungi

Coronavirus Disease 2019-Associated Invasive Fungal Infection.

Journal article

Johnson, Melissa D|0000-0002-6606-9460

Schwartz, Ilan S|0000-0002-7522-0281

ofab510

12

Duke

School of Medicine

Clinical Science Departments

Medicine

Medicine, Infectious Diseases

Published

8